Free accessResearch articleFirst published online 2002-2
Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation
We performed a single-blind, sequential-design study to investigate the effects of concomitant oral tamsulosin 0.8 mg/day on the pharmacokinetics and safety of intravenous theophylline 5 mg/kg in healthy subjects. Ten healthy volunteers aged 19–39 years received placebo on study days 0, 1, 2 and 10 and tamsulosin on days 3–9. Theophylline was administered intravenously on days 1 and 9. Theophylline and tamsulosin pharmacokinetic data were determined following administration of the drugs on days 1 and 9 and day 9, respectively. No differences were observed in theophylline pharmacokinetic parameters with and without concomitant tamsulosin, and there were no abnormalites in tamsulosin pharmacokinetic data. Some significant changes in vital signs and a number of mild adverse reactions were reported, but the overall safety profile of tamsulosin and theophylline was acceptable. The results of the study suggest that no dose adjustment in tamsulosin is necessary when it is administered concomitantly with theophylline.
PriceDTSchwinnDALomasneyJWAllenLFCaronMGLefkowitzRJ: Identification, quantification and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol1993; 150: 546–551
2.
LeporHTangRShapiroE: The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate1993; 22: 301–307
3.
ChappleCRBurtRPAnderssonPOGreengrassPWyllieMMarshallI: Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol1994; 74: 585–589
4.
MirandaHFRamirezHCastilloOMinnemaKPPinardiG: α1A-Adrenergic receptors in the isolated human prostate. Pharmacol Commun1994; 4: 181–188
5.
ForrayCBardJAWetzelJMChiuGShapiroETangR: The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1C-subtype. Mol Pharmacol1994; 45: 703–708
6.
AbramsPSchulmanCCVaageSfor the European Tamsulosin Study Group: Tamsulosin, a selective α1C-adrenoceptor antagonist. A randomized, placebo-controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol1995; 76: 325–336
7.
ChappleCR: Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol1996; 29: 129–144
8.
ChappleCRWyndaeleJJNordlingJBoeminghausFYpmaAFAbramsPon behalf of the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol1996; 29: 155–167
9.
SchulmanCCCortvriendJJonasULockTMVaageSSpeakmanMJon behalf of the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol1996; 29: 145–154
10.
LeporH: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology1998; 51: 892–900
11.
LeporH: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology1998; 51: 901–906
12.
NarayanPTewariA: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol1998; 160: 1701–1706
13.
KawabeKUenoATakimotoYAsoYKatoHon behalf of the YM617 Clinical Study Group: Use of the α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol1990; 144: 908–912
WildeMIMcTavishD: Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs1996; 52: 883–898
16.
JonkmanJH: Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol1986; 78: 736–742
17.
UptonRA: Pharmacokinetic interactions between theophylline and other medication (Part I). Clin Pharmacokinet1991; 20: 66–80
18.
HaHRChenJFreiburghausAUFollathF: Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Pharmacol1995; 39: 321–326
19.
Respiratory Smooth Muscle Relaxants.Theophylline. In: AHFS Drug Information (McEvoyGKLitvakK, eds). Bethesda, MD: American Society of Hospital Pharmacists, 1993
20.
KamimuraHOishiSMatushimaHWatanabeTHiguchiSHallM: Identification of cytochrome P450 isozymes involved in metabolism of the α1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica1998; 28: 909–922
21.
LukeDRHalstensonCEOpsahlJAMatzkeGR: Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther1990; 48: 503–508
22.
CapraniOSveinsdottirELassenN: SHAM, a method for biexponential curve resolution using initial slope, height, area, and moment of experimental decay type curve. J Theor Biol1975; 52: 299–315
23.
DiStefanoJJIII: Noncompartmental vs compartmental analysis. Some bases for choice. Am J Physiol1982; 243: R1–R6
24.
Food and Drug Administration: Guidance: Statistical Procedures for Bioequivalence Studies Using a Standard Two-treatment Crossover Design.Rockville, MD: Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration;1992
25.
SchuirmanDJ: A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm1987; 15: 675–680
26.
BlanchardJHarveyS: Comparison of ultrafiltration devices for assessing theophylline protein binding. Ther Drug Monit1990; 12: 398–403
